Biotest AG Logo

Biotest AG

Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.

BIO3 | F

Overview

Corporate Details

ISIN(s):
DE0005227201 (+1 more)
LEI:
529900JVX7RPXBLYUD89
Country:
Germany
Address:
Landsteinerstraße 5, 63303 Dreieich
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biotest AG is a global biopharmaceutical company that develops, manufactures, and markets plasma protein products and biotherapeutic drugs. The company's value chain extends from pre-clinical and clinical development to worldwide marketing and distribution. Its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine to treat conditions such as haemophilia, immune deficiencies, and severe infections. Biotest also produces Human Serum Albumin for use as an excipient in biotechnological, pharmaceutical, and diagnostic applications. The company maintains an active development pipeline for next-generation immunoglobulins and other therapies. Since 2022, Biotest has been part of the Grifols group.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 10:07
Regulatory Filings
Biotest obtains approval for new human fibrinogen Prufibry in Germany
English 10.7 KB
2025-11-07 15:19
Pre-Annual General Meeting Information
Biotest AG: Extraordinary general meeting convened again at the request of Grif…
English 7.0 KB
2025-10-23 13:16
Pre-Annual General Meeting Information
Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
English 6.0 KB
2025-10-09 17:30
Regulatory Filings
Biotests Yimmugo launches in the United States
English 7.4 KB
2025-09-19 15:00
Pre-Annual General Meeting Information
Biotest AG: Extraordinary general meeting convened at the request of Grifols S.…
English 6.3 KB
2025-09-17 00:00
Registration Form
Articles of association - as of July 02, 2025
English 133.4 KB
2025-08-04 13:00
Legal Proceedings Report
Biotest AG receives a request from Grifols S.A. to convene an extraordinary gen…
English 6.8 KB
2025-07-02 18:08
AGM Information
Biotest AG: Annual General Meeting approves dividend distribution
English 7.8 KB
2025-06-23 17:03
Earnings Release
Biotests positive fibrinogen phase III trial results published in The Lancets e…
English 14.5 KB
2025-06-20 00:00
Regulatory Filings
Berichtigung der Veröffentlichung vom 17.04.2025
German 303.6 KB
2025-06-03 16:51
Delisting Announcement
Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with …
English 8.2 KB
2025-05-28 17:00
Board/Management Information
Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
English 8.1 KB
2025-05-12 17:35
Earnings Release
Biotest confirms Guidance for 2025
English 11.5 KB
2025-05-12 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 414.7 KB
2025-05-05 00:00
Remuneration Information
Bericht zur Gleichstellung und Entgeltgleichheit nach EntgTranspG als Anlage de…
German 11.9 KB

Automate Your Workflow. Get a real-time feed of all Biotest AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biotest AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biotest AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-11-29 Bernöster, Dr. Katrin Other Sell None 15,640.00 EUR
2021-11-29 Realsoul Holding S.A. Close relation Buy None 1,713.60 EUR
2021-11-18 Fleck, Stephan Other Sell None 120,870.00 EUR
2021-11-18 Schüttrumpf, Dr. Jörg Other Sell None 99,895.50 EUR
2021-11-18 Reinecke, Dr. Martin Other Sell None 37,715.00 EUR
2021-11-18 Moritz, Michael Other Sell None 35,460.00 EUR

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.